Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lawyer, C.
Right arrow Articles by Watabe, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lawyer, C.
Right arrow Articles by Watabe, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1996) 37, 599-604
© 1996 The British Society for Antimicrobial Chemotherapy

brief-report

Effects of synthetic form of tracheal antimicrobial peptide on respiratory pathogens

Carl Lawyera, Sudha Paia, Misako Watabeb, Haithem Bakira, Lanie Eagletona and Kounosuke Watabeb,*

aDepartment of Internal Medicine Pulmonary Division, School of Medicine, Southern Illinois University Springfield, Illinois 62702, USA bDepartment of Medical Microbiology and Immunology, School of Medicine, Southern Illinois University Springfield, Illinois 62702, USA

Received 31 May 1995; returned 31 August 1995; accepted 10 October 1995

*Corresponding author

We have synthesized a C-terminal portion of tracheal antimicrobial peptide (TAP) with 38 amino acids and tested it for efficacy on various clinical isolates of Pseudomonas aeruginosa strains from patients with cystic fibrosis and also on Aspergillus fumigatus. Our results indicate that the synthetic TAP has both potent bactericidal and fungicidal activities and that a combination of TAP and amphotericin B showed strong additive effects of growth inhibition on A. fumigatus. These results suggest that TAP is potentially an effective therapy for Aspergillus and multi-drug-resistant Pseudomonas, pathogens that are often a serious threat to patients with cystic fibrosis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
U. Schwab, P. Gilligan, J. Jaynes, and D. Henke
In Vitro Activities of Designed Antimicrobial Peptides against Multidrug-Resistant Cystic Fibrosis Pathogens
Antimicrob. Agents Chemother., June 1, 1999; 43(6): 1435 - 1440.
[Abstract] [Full Text]

Home page
 Antimicrob. Agents Chemother.Home page
A. J. De Lucca and T. J. Walsh
Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens
Antimicrob. Agents Chemother., January 1, 1999; 43(1): 1 - 11.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.